Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation

Among the several next-generation tyrosine kinase inhibitors (TKIs) tested against uncommon EFGR alterations, poziotinib has been demonstrated to be a powerful agent for metastatic non-small-cell lung cancer (mNSCLC) with aberrations in HER2 exon 20, and FDA approval is being sought in the previousl...

Descripción completa

Detalles Bibliográficos
Autores principales: Prelaj, Arsela, Bottiglieri, Achille, Bhat, Gajanan, Washington, Rocky, Calareso, Giuseppina, Greco, Gabriella Francesca, Ferrara, Roberto, Brambilla, Marta, De Toma, Alessandro, Occhipinti, Mario, Manglaviti, Sara, Soro, Alberto, Ganzinelli, Monica, Lo Russo, Giuseppe, Proto, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215205/
https://www.ncbi.nlm.nih.gov/pubmed/35756673
http://dx.doi.org/10.3389/fonc.2022.902967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215205/
https://www.ncbi.nlm.nih.gov/pubmed/35756673
http://dx.doi.org/10.3389/fonc.2022.902967

Ejemplares similares